glp-1 treatment for newly diagnosed diabetes guidelines The New ADA/EASD Type 1 Adult Mapping the effectiveness and risks

Finally, following recent concerns by regulatory agencies regarding a potential increase in suicidal behavior associated with GLP-1RAs 206 , we found 1 recent pharmacovigilance report showing 0.6% suicidal events among 41,236 safety reports for these medications 207 and an emulated target trial of 86,418 older adults with T2DM that did not identify any difference in suicidal ideation or behavior between GLP-1RAs and other antidiabetic medications over 1.5 years 208

Several clinical trials are currently underway in Australia, which are investigating the potential effects of GLP-1RA semaglutide [88] related to alcohol abuse

Others want nothing to do with needles, prescriptions, or the gastrointestinal side effects that come with pharmaceutical doses

Recent comprehensive reviews of the many GLP-1 agonists that have come to the market in the last 20 years have been published elsewhere [8,37]